Kidney Week

Abstract: SA-PO0685

Timing of Anticoagulation Resumption and Risk of Delayed Hematoma After Kidney Biopsy: A Single-Center Cohort Study

Session Information

• Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research - Other
  October 24, 2026 | Location: Exhibit Hall A, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Glomerular Diseases

• 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Authors

• Leite, Petra Mimi, Yale School of Medicine Department of Internal Medicine, New Haven, Connecticut, United States

Petra Mimi Leite

• Reed, Abigail, Yale School of Medicine Department of Internal Medicine, New Haven, Connecticut, United States

Abigail Reed

• Sadarangani, Sagar S., Yale School of Medicine Department of Internal Medicine, New Haven, Connecticut, United States

Sagar S. Sadarangani, MBBS

• Javed, Daris, Yale School of Medicine Department of Internal Medicine, New Haven, Connecticut, United States

Daris Javed

• Kent, Candice, Yale School of Medicine Department of Internal Medicine, New Haven, Connecticut, United States

Candice Kent, MS

• Shaw, Melissa M., Yale School of Medicine Department of Internal Medicine, New Haven, Connecticut, United States

Melissa M. Shaw

• Moledina, Dennis G., Yale School of Medicine Department of Internal Medicine, New Haven, Connecticut, United States

Dennis G. Moledina, MD, PhD, FASN

Background

Kidney biopsy is an effective and commonly used method to diagnose kidney injury and disease. Inherent bleeding risk associated with this procedure requires anticoagulation to be paused before biopsy; however, there are no data to support optimal timing of resumption of anticoagulation after biopsy. Here we examined whether the timing of the resumption of anticoagulation is associated with delayed hematoma.

Methods

From a single-center retrospective cohort of kidney biopsy patients, we identified 90 patients who were: admitted at the time of biopsy, on anticoagulation prior to biopsy, which was held and resumed post procedure, with no immediate hematoma. The primary outcome was delayed hematoma within 30 days of procedure. We compared baseline characteristics, comorbidities, and laboratory values that may contribute to differences in delayed hematoma risk between early and late resumers at the 24-hour cutoff. We also evaluated the anticoagulation resumption timing at ≤24, ≤48, and ≤72-hour cutoffs while adjusting for confounders.

Results

Of the 90 patients evaluated 7 (7.8%) developed delayed hematoma within 30 days. The timing of anticoagulation resumption was not significantly associated with delayed hematoma at any time cutoff. Notably, early resumers (≤24h) had a higher hematoma rate than late resumers (14.3% vs 3.6%); however, this was not statistically significant. The only independent predictor of delayed hematoma was lower pre-biopsy hematocrit [OR 0.76, 95% CI 0.60–0.98, p=0.02–0.04].

Conclusion

These findings suggest that early resumption of anticoagulation after kidney biopsy may be safe, though the small sample size limits firm conclusions.

Funding

• NIDDK Support